More Info on the following website:

MEDITRANS represents a multidisciplinary integrated project dealing with targeted nanomedicines. Platform technologies will be developed with broad applicability to disease treatment, as exemplified by the choice for chronic inflammatory disorders (rheumatoid arthritis, Crohn’s disease, multiple sclerosis), and cancer as target pathologies. Nanomedicines (based on carrier materials like polymeric and lipidic nanoparticles, nanotubes, and fullerenes) will be endowed with superior targeting and (triggerable) drug release properties.

In parallel, MRI imaging probes will be designed that report on the localisation of the targeted nanomedicines, specific biomarkers, the drug release process and therapeutic outcome (imaging-guided drug delivery).

The consortium consists of 30 partners from 9 EU member states (including 1 new member state) and 3 associated states, and includes 13 industrial companies, 11 universities and 6 research institutes. The total budget is € 16.1 million with € 11 million as EC contribution and € 5.1 million as industrial support.

The MEDITRANS project has clear potential to forward targeted nanomedicines to the clinic, and will contribute to improved structural collaboration between industry and academia.